Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 6/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9759392 | 0.85 | HTT (0.33) | CYP1A2CYP2C19ALDH1A1LMNARECQL | |
| SCHEMBL9568576 | 0.81 | HTT (0.38) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL9615906 | 0.80 | HTT (0.43) | ALDH1A1TSHRLMNARECQLMAPT | |
| SCHEMBL600325 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNAMAPTTDP1 | |
| SCHEMBL2074919 | 0.77 | HTT (0.35) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL9568601 | 0.76 | NR1I2 (0.35) | ALDH1A1LMNARECQLMAPTTDP1 | |
| SCHEMBL9101581 | 0.75 | HTT (0.43) | CYP2C19ALDH1A1TSHRLMNARECQL | |
| SCHEMBL17417188 | 0.75 | HTT (0.54) | CYP2C19ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL9542136 | 0.75 | CA2 (0.36) | ALDH1A1LMNARECQLMAPTTDP1 | |
| SCHEMBL28564255 | 0.75 | LMNA (0.42) | CYP1A2CYP2C19ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122163-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-04-17 | — | — | US | disclosed |
| EP-4467547-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023136213-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2023-07-20 | — | — | WO | disclosed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120095233-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8119655-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-21 | — | — | US | disclosed |
| EP-2133349-B1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2011-01-12 | — | — | EP | disclosed |
| EP-2223925-A1 | Kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-2133349-A1 | Kinase inhibitors | Takeda San Diego, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009129401-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | WO | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2079696-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095233-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CYP1A2 4036/4885CYP2C19 3258/4885ALDH1A1 3887/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CYP1A2 3551/4885CYP2C19 1740/4885ALDH1A1 4208/4885 |
| US-20250122163-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | CCNE1, NAP1L1, CRYZ | CYP1A2 708/4885CYP2C19 2138/4885ALDH1A1 1010/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CYP1A2 4036/4885CYP2C19 3258/4885ALDH1A1 3887/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CYP1A2 4036/4885CYP2C19 3258/4885ALDH1A1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.